Healthcare provider profile · identity verified

Mark C Magged, M.D.

Family Practice · WHITTIER, CA · NPI 1417045436

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	519	168
Amlodipine Besylate	Amlodipine Besylate	381	112
Rosuvastatin Calcium	Rosuvastatin Calcium	365	118
Lisinopril	Lisinopril	350	104
Losartan Potassium	Losartan Potassium	324	98
Levothyroxine Sodium	Levothyroxine Sodium	285	76
Metformin Hcl	Metformin Hcl	219	66
Simvastatin	Simvastatin	186	60
Alendronate Sodium	Alendronate Sodium	184	60
Tamsulosin Hcl	Tamsulosin Hcl	176	56
Gabapentin	Gabapentin	173	53
Furosemide	Furosemide	161	53
Alprazolam	Alprazolam	148	42
Eliquis	Apixaban	138	29
Hydrochlorothiazide	Hydrochlorothiazide	132	43
Metoprolol Tartrate	Metoprolol Tartrate	124	39
Famotidine	Famotidine	117	38
Omeprazole	Omeprazole	117	39
Pantoprazole Sodium	Pantoprazole Sodium	113	36
Albuterol Sulfate Hfa	Albuterol Sulfate	108	47
Fluticasone Propionate	Fluticasone Propionate	106	56
Escitalopram Oxalate	Escitalopram Oxalate	99	35
Metoprolol Succinate	Metoprolol Succinate	90	29
Allopurinol	Allopurinol	86	24
Benazepril Hcl	Benazepril Hcl	85	26
Clopidogrel	Clopidogrel Bisulfate	83	25
Atenolol	Atenolol	81	24
Potassium Chloride	Potassium Chloride	80	22
Meloxicam	Meloxicam	79	29
Vitamin D2	Ergocalciferol (Vitamin D2)	79	28
Montelukast Sodium	Montelukast Sodium	77	23
Carvedilol	Carvedilol	76	21
Ibuprofen	Ibuprofen	70	29
Lorazepam	Lorazepam	69	18
Jardiance	Empagliflozin	67	20
Sertraline Hcl	Sertraline Hcl	66	19
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	64	17
Zolpidem Tartrate	Zolpidem Tartrate	64	14
Ezetimibe	Ezetimibe	59	21
Pravastatin Sodium	Pravastatin Sodium	59	16
Finasteride	Finasteride	58	18
Tramadol Hcl	Tramadol Hcl	58	22
Diclofenac Sodium	Diclofenac Sodium	56	21
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	51	21
Donepezil Hcl	Donepezil Hcl	48	14
Lansoprazole	Lansoprazole	46	suppressed
Lovastatin	Lovastatin	45	13
Pioglitazone Hcl	Pioglitazone Hcl	43	14
Hydralazine Hcl	Hydralazine Hcl	39	13
Quetiapine Fumarate	Quetiapine Fumarate	38	11
Cephalexin	Cephalexin	37	33
Baclofen	Baclofen	36	14
Paroxetine Hcl	Paroxetine Hcl	36	11
Glipizide	Glipizide	35	11
Temazepam	Temazepam	35	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	34	12
Meclizine Hcl	Meclizine Hcl	34	12
Synthroid	Levothyroxine Sodium	34	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	34	17
Duloxetine Hcl	Duloxetine Hcl	32	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	32	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	31	14
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	30	suppressed
Spironolactone	Spironolactone	30	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	29	11
Ibandronate Sodium	Ibandronate Sodium	29	suppressed
Xarelto	Rivaroxaban	29	suppressed
Ozempic	Semaglutide	27	suppressed
Tizanidine Hcl	Tizanidine Hcl	27	suppressed
Mirtazapine	Mirtazapine	26	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	26	17
Celecoxib	Celecoxib	25	suppressed
Januvia	Sitagliptin Phosphate	25	suppressed
Trazodone Hcl	Trazodone Hcl	25	suppressed
Memantine Hcl	Memantine Hcl	24	suppressed
Metolazone	Metolazone	24	suppressed
Nitroglycerin	Nitroglycerin	23	17
Azithromycin	Azithromycin	22	21
Hydrocortisone	Hydrocortisone	22	suppressed
Myrbetriq	Mirabegron	22	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	21	suppressed
Digoxin	Digoxin	21	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	21	suppressed
Methocarbamol	Methocarbamol	21	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	21	suppressed
Folic Acid	Folic Acid	20	suppressed
Terazosin Hcl	Terazosin Hcl	19	suppressed
Aripiprazole	Aripiprazole	18	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	18	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	18	suppressed
Nystatin	Nystatin	18	suppressed
Ipratropium Bromide	Ipratropium Bromide	17	suppressed
Ketoconazole	Ketoconazole	17	12
Mupirocin	Mupirocin	17	suppressed
Sildenafil Citrate	Sildenafil Citrate	17	suppressed
Glimepiride	Glimepiride	16	suppressed
Irbesartan	Irbesartan	16	suppressed
Diazepam	Diazepam	15	suppressed
Metformin Hcl Er	Metformin Hcl	15	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	14	suppressed
Levetiracetam	Levetiracetam	14	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	14	suppressed
Bupropion Xl	Bupropion Hcl	13	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	13	12
Doxazosin Mesylate	Doxazosin Mesylate	13	suppressed
Minocycline Hcl	Minocycline Hcl	13	suppressed
Naproxen	Naproxen	13	suppressed
Propranolol Hcl	Propranolol Hcl	13	suppressed
Symbicort	Budesonide/Formoterol Fumarate	13	suppressed
Valsartan	Valsartan	13	suppressed
Azelastine Hcl	Azelastine Hcl	12	suppressed
Clonidine Hcl	Clonidine Hcl	12	suppressed
Glipizide Er	Glipizide	12	suppressed
Levemir Flexpen	Insulin Detemir	12	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	12	12
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	12	suppressed
Amiodarone Hcl	Amiodarone Hcl	11	suppressed
Fenofibrate	Fenofibrate,micronized	11	suppressed
Klor-Con 8	Potassium Chloride	11	suppressed
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	11	suppressed
Prolia	Denosumab	11	suppressed
Tramadol Hcl-Acetaminophen	Tramadol Hcl/Acetaminophen	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error